



March 25, 2024

Santen Announces Completion of Share Buyback

Santen Pharmaceutical Co., Ltd. (Head Office: Osaka; President and CEO: Takeshi Ito) announced completion of the share buyback as stated below. The share buyback was implemented in accordance with Article 156 of the Companies Act (Japan), as applied pursuant to Article 165, paragraph 3. The total realized amount of repurchase did not reach the maximum amount of repurchase since the share price of the Company was at a higher level than the price at which the Company expected to purchase the shares at the time of the resolution at the meeting of the Board of Directors.

1. Class of shares repurchased : Common shares
2. Total number of shares repurchased : 0 shares
3. Total amount of repurchase : 0 yen
4. Period of repurchase : March 1, 2024 to March 22, 2024
(execution date basis)
5. Method of repurchase : Open-market repurchase by the discretionary trading method

(Reference)

1. Details of the resolution at the meeting of the Board of Directors (announced on May 11, 2023)
 - (1) Class of shares to be repurchased : Common shares
 - (2) Total number of shares to be repurchased : 18,750,000 shares (maximum)
*Representing 5.0% of the total number of shares outstanding (excluding treasury shares)
 - (3) Total amount of repurchase : 24.5 billion yen (maximum)
 - (4) Period of repurchase : May 12, 2023 to March 22, 2024

2. Total Company's own shares repurchased through March 22, 2024, pursuant to the above Board resolution

- (1) Total number of shares repurchased : 12,571,400 shares
- (2) Total amount of repurchase : 16,178,351,350 yen

Contact:

Guillaume Sakuma
Global Head of IR, IR Group
E-mail: ir@santen.com

About Santen

As a specialized company dedicated to eye health, Santen aspires to contribute to the realization of “Happiness with Vision” by providing products and services to patients, consumers, and medical professionals around the world. Since its establishment, and guided by its CORE PRINCIPLE, “*Tenki ni sanyo suru*,” Santen has been committed to helping people maintain and improve their eye health for more than 130 years. Santen is engaged in the global research and development, manufacturing, and sales and marketing of pharmaceutical products in the field of eye care, supporting the eye health of approximately 50 million people in more than 60 countries and regions worldwide. Santen’s mission is to provide essential and significant value to patients and society in the prevention, diagnosis, and treatment of eye diseases through products and services created from its expertise in the ophthalmology field and from the patient's perspective. To create a future in which as many patients as possible can lead happy and fulfilling lives, Santen is committed to doing its utmost to realize a society in which people around the world can experience “Happiness with Vision.”

For more information, please visit Santen’s website <https://www.santen.com/en>.